NEW DELHI, 13 JULY 

The Indian Council of Medical Research (ICMR) reports that enrolment for the Phase-III clinical trial of DengiAll, India's first indigenous dengue vaccine, is expected to conclude by October. Approximately 10,500 participants are targeted for this trial, with 8,000 already enrolled at centres across Pune, Chennai, Kolkata, Delhi, and Bhubaneswar. The trial will assess the safety and efficacy of the vaccine, which has shown no safety concerns in earlier trials. Dengue remains a significant public health issue in India. According to government data, around 12,043 dengue cases were reported as of March this year. In 2024, 2.3 lakh cases and 297 deaths had been recorded.